stockrow
Friday 6 November 2026
Export TLX’s income statement to Excel — free account
Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited’s revenue for fiscal 2025 (year ended December 2025) was $803.8 million, up 55.6% from fiscal 2024.
9.63
0.21
+2.23%
Follow TLX
Alert me
Telix Pharmaceuticals Limited (TLX) P/B ratio
Telix Pharmaceuticals Limited has no meaningful P/B ratio: its trailing twelve-month book value is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| TLX Telix Pharmaceuticals Limited | n/m |
| CELC Celcuity, Inc. compare | n/m |
| IDYA IDEAYA Biosciences, Inc. compare | 2.9× |
| ELVN Enliven Therapeutics, Inc. compare | 3.3× |
| DNLI Denali Therapeutics Inc. compare | 4.0× |
| DYN Dyne Therapeutics, Inc. compare | 4.1× |
| VKTX Viking Therapeutics, Inc. compare | 5.2× |
| VRDN Viridian Therapeutics, Inc. compare | 5.5× |
| TARS Tarsus Pharmaceuticals, Inc. compare | 30.1× |
| Biotechnology industry median | 2.0× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))